CRISPR Therapeutics AG (CRSP)
60.76
+3.68
(+6.46%)
USD |
NASDAQ |
Aug 25, 14:46
CRISPR Therapeutics Shareholders Equity (Quarterly) : 1.747B for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.747B |
| March 31, 2026 | 1.815B |
| December 31, 2025 | 1.922B |
| September 30, 2025 | 1.916B |
| June 30, 2025 | 1.711B |
| March 31, 2025 | 1.829B |
| December 31, 2024 | 1.932B |
| September 30, 2024 | 1.940B |
| June 30, 2024 | 1.981B |
| March 31, 2024 | 2.084B |
| December 31, 2023 | 1.883B |
| September 30, 2023 | 1.728B |
| June 30, 2023 | 1.816B |
| March 31, 2023 | 1.855B |
| December 31, 2022 | 1.875B |
| September 30, 2022 | 1.954B |
| June 30, 2022 | 2.091B |
| March 31, 2022 | 2.245B |
| December 31, 2021 | 2.399B |
| September 30, 2021 | 2.513B |
| June 30, 2021 | 2.604B |
| Date | Value |
|---|---|
| March 31, 2021 | 1.805B |
| December 31, 2020 | 1.664B |
| September 30, 2020 | 1.343B |
| June 30, 2020 | 910.67M |
| March 31, 2020 | 886.10M |
| December 31, 2019 | 939.42M |
| September 30, 2019 | 591.88M |
| June 30, 2019 | 367.68M |
| March 31, 2019 | 379.81M |
| December 31, 2018 | 392.20M |
| September 30, 2018 | 417.31M |
| June 30, 2018 | 265.15M |
| March 31, 2018 | 290.34M |
| December 31, 2017 | 187.83M |
| September 30, 2017 | 178.96M |
| June 30, 2017 | 197.80M |
| March 31, 2017 | 215.18M |
| December 31, 2016 | 232.85M |
| September 30, 2016 | 123.08M |
| June 30, 2016 | 135.38M |
| March 31, 2016 | 89.93M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Vertex Pharmaceuticals, Inc. | 20.25B |
| BeOne Medicines Ltd. | 5.174B |
| Basilea Pharmaceutica AG | -- |
| Santhera Pharmaceuticals Holding AG | -- |
| AC Immune SA | 43.60M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 2.651B |
| Total Liabilities (Quarterly) | 904.22M |
| Debt to Equity Ratio | 0.4487 |
| Current Ratio | 17.85 |
| Net Debt Paydown Yield | -2.14% |